# Avelumab for People With Recurrent Respiratory Papillomatosis

> **NCT02859454** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 13 (actual)

## Conditions studied

- Recurrent Respiratory Papillomatosis
- Juvenile Laryngeal Papilloma
- Laryngeal Papilloma, Recurrent
- Respiratory Papillomatosis
- Human Papilloma Virus

## Interventions

- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT02859454
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-06
- **Primary completion:** 2018-06-30
- **Final completion:** 2021-09-15
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2021-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02859454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02859454, "Avelumab for People With Recurrent Respiratory Papillomatosis". Retrieved via MORVS 2026-10-09 from https://api.morvs.ai/clinical/NCT02859454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*